uniQure NV (QURE) Statistics

uniQure NV (QURE) is a leading gene therapy company that is focused on providing potentially curative options for patients with severe genetic diseases. The company's innovative platform uses gene therapy to deliver therapeutic payloads directly to the patient's cells, addressing the underlying genetic cause of the disease. This approach has the potential to transform the treatment of genetic diseases and improve the lives of patients. uniQure NV's stock statistics reflect the growing interest in gene therapy and the company's potential for future growth. As of the latest data available, the stock has a market capitalization of $1.5 billion and a current share price of $40.70.

In terms of valuation metrics, uniQure NV has a price-to-earnings (P/E) ratio of -10.88, which indicates that the company is currently not profitable. However, the company's revenue per share is $0.13, suggesting that uniQure NV has the potential for future earnings growth. uniQure NV's enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio is -10.41, indicating that the company is not generating positive EBITDA. This metric is often used to evaluate the valuation of companies in the biotech sector. uniQure NV's profit margin is -670.69%, reflecting the company's current lack of profitability. However, it is important to note that many biotech companies operate at a loss in their early stages of development.